Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

    • naloxone

    - PMLiVE

    FDA unveils new voucher programme to accelerate drug review process

    The programme is designed to reduce the review time for companies supporting US national interests

    - PMLiVE

    FDA approves Bavarian Nordic’s chikungunya vaccine for individuals aged from 12 years

    The mosquito-borne viral disease has been reported across many popular travel destinations

    - PMLiVE

    Roche’s Evrysdi tablet formulation granted FDA approval for spinal muscular atrophy

    The progressive neuromuscular disease affects approximately one in every 10,000 babies globally

    - PMLiVE

    FDA accepts updated protocol for Annovis’ phase 3 Alzheimer’s disease study

    The company hopes the revised protocol will accelerate the development timeline of buntanetap

    - PMLiVE

    FDA approves BridgeBio Pharma’s Attruby to treat rare heart disease ATTR-CM

    Transthyretin amyloid cardiomyopathy affects up to 500,000 people worldwide

    - PMLiVE

    UCB’s Bimzelx granted FDA approval to treat hidradenitis suppurativa in adults

    The inflammatory skin disease affects approximately one in every 100 people in the US

    - PMLiVE

    Novavax announces FDA clinical hold lift on phase 3 COVID-19/flu vaccine study

    The serious adverse event reported was found to be unrelated to the vaccine

    - PMLiVE

    FDA approves Autolus Therapeutics’ Aucatzyl to treat acute lymphoblastic leukaemia

    Approximately 8,400 adults are diagnosed with the aggressive blood cancer every year in the US and EU

    - PMLiVE

    FDA approves Journey Medical’s Emrosi to treat inflammatory lesions of rosacea

    The long-term skin condition affects more than 16 million people in the US

    - PMLiVE

    Novartis’ Scemblix granted FDA accelerated approval in newly diagnosed CML

    Approximately 9,280 new cases of the disease are expected to be diagnosed in the US this year

    - PMLiVE

    Astellas’ Vyloy approved by FDA as first-line gastric cancer combination treatment

    Approximately 26,890 new cases of gastric cancer will be diagnosed in the US this year

    - PMLiVE

    AbbVie’s continuous Parkinson’s disease therapy Vyalev approved by FDA

    More than ten million people worldwide are living with the neurological disorder

    Subscribe to our email news alerts

    Latest content

    Latest intelligence

    Quick links